Context Therapeutics (CNTX) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Context Therapeutics (CNTX) over the past year, losing 55.4% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -98.8% for CTXR. Context Therapeutics is the larger company by market cap ($14.7 million vs $14.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | CTXR |
|---|---|---|
| Share price | $0.16 | $0.5085 |
| Market cap | $14.70M | $13.96M |
| 1-day change | -5.10% | +2.27% |
| YTD return | -89.12% | -34.56% |
| 1-year return | -85.32% | -55.39% |
| 5-year return | -96.86% | -98.79% |
| EPS (TTM) | $-0.46 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-36.12M | $-39.74M |
| 52-week high | $3.62 | $1.54 |
| 52-week low | $0.153 | $0.37 |
| Distance from 52-week high | -95.58% | -66.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +2418.75% | +686.63% |
| Average volume | 1.42M | 275.44K |
| Shares outstanding | 91.88M | 27.45M |
| Employees | 15 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed CNTX by 29.9 percentage points over the past year.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CNTX vs CTXR FAQ
Which is bigger, Context Therapeutics or Citius Pharmaceuticals?
Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.96M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CNTX or CTXR?
CTXR returned -55.39% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.